Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease Treatment Guidelines

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the results of a recently published clinical research study that demonstrates improved physician adherence to chronic kidney disease (CKD) treatment guidelines

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Enters into Definitive Agreement to Acquire Assets of Pathology, Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 10, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that it has entered into a definitive agreement to acquire substantially all of the operating assets of Pathology, Inc.

LabCorp Launches New Enhanced Report for Medical Drug Monitoring

The LabCorp MedWatch ® ToxAssure ® report joins a suite of proprietary decision support tools to assist clinicians in patient management BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 30, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that MedTox Laboratories

LabCorp is Scheduled to Present at the 2015 Credit Suisse Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 3, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the 2015 Credit Suisse Healthcare Conference . LabCorp’s presentation is planned for Tuesday, November 10, 2015 at 1:00 PM (ET) .

Laboratory Corporation of America® Holdings Announces 2015 Third Quarter Results

Q3 Net revenue of $2.3 billion , up 46% over last year Q3 Diluted EPS of $1.49 ; Q3 Adjusted EPS of $2.07 , up 15% over last year Q3 Free Cash Flow of $220 million , up 79% over last year 2015 Adjusted EPS guidance updated to $7.80 - $7.95 from $7.75 - $8.00 BURLINGTON, N.C. --(BUSINESS WIRE)--Oct.

LabCorp Acquires Safe Foods International Holdings

Transaction Expands Capabilities in Food and Beverage product-development and product-integrity BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 23, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the acquisition of Safe Foods International Holdings, LLC (SFIH)

Covance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Two Years in a Row

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 19, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Covance Drug Development (“Covance”) has been awarded the 2015 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award.

LabCorp to Offer New PD-L1 Test for Bristol-Myers Squibb’s OPDIVO® Following Collaboration in Clinical Trial

Test Launch Demonstrates that Combined LabCorp-Covance Capabilities Provide Best in Class Solutions for Development and Commercialization of Diagnostics Linked to Innovative Medicines BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 12, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® )

LabCorp to Follow Pivotal Role in Clinical Trial of Merck’s Keytruda® by Offering PD-L1 Companion Diagnostic

Test Launch Demonstrates that Combined LabCorp-Covance Capabilities Make the Company Best-in-Class Partner for Development and Commercialization of Companion Diagnostics BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 2, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today